Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.18 USD | +18.30% | +15.04% | -23.50% |
04-16 | CareDx Appoints John Hanna as CEO, President | MT |
04-16 | CareDx, Inc Appoints John W. Hanna as Chief Executive Officer | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-23.50% | 477M | C- | ||
-18.88% | 11.03B | A- | ||
+53.75% | 3.5B | D+ | ||
-32.50% | 2.23B | C | ||
-14.31% | 2.16B | - | B- | |
-26.83% | 1.54B | C+ | ||
+28.55% | 1.12B | B- | ||
-3.28% | 737M | C+ | ||
-43.27% | 411M | C- | ||
+17.30% | 342M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CDNA Stock
- Ratings CareDx, Inc